How many Tremelimumab clinical trials are there?

234 Tremelimumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 40 are actively recruiting participants. 97 are marked completed.

Are Tremelimumab clinical trials recruiting in 2026?

Yes — 40 Tremelimumab trials are actively recruiting in 2026, with 206 U.S. sites across 29 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Tremelimumab being studied for?

Tremelimumab is being studied for Hepatocellular Carcinoma, Colorectal Cancer, Bladder Cancer, Breast Cancer, Advanced Solid Tumors and 413 more. The trials are grouped by indication on this page.

What phase is Tremelimumab in?

Tremelimumab clinical trials span 20 Phase 3, 122 Phase 2, 48 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Tremelimumab clinical trials?

The lead sponsor across the most Tremelimumab trials is AstraZeneca, with 111 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Tremelimumab Clinical Trials (2026): 234 Studies for Hepatocellular Carcinoma & Colorectal Cancer

Creator: Hipa.ai Research
Published: 2026-06-02T16:44:37.437Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 16, 2026.

234 Tremelimumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 163 indications (including Hepatocellular Carcinoma & Colorectal Cancer) and 36,358 total planned enrollment. 20 Phase 3 Tremelimumab trials and 122 Phase 2 are listed. 44 Tremelimumab clinical trials are actively recruiting at 206 U.S. sites across 29 states. Most recent activity: NCT03288532 (Dec 2034).

Where to Participate: All Tremelimumab Trial Sites in the U.S. (206 sites across 29 states)

Every actively recruiting Tremelimumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AZ	CTCA at Western Regional Medical Center	Goodyear85338	NCT07288034	Map
AZ	Research Site	Phoenix85054	NCT06921785	Map
CA	Alta Bates Summit Medical Center-Herrick Campus	Berkeley94704	NCT07166406	Map
CA	Sutter Cancer Centers Radiation Oncology Services-Cameron Park	Cameron Park95682	NCT07166406	Map
CA	City of Hope Corona	Corona92882	NCT07288034	Map
CA	City of Hope /ID# 261468	Duarte91010	NCT06109272	Map
CA	City of Hope Medical Center	Duarte91010	NCT07288034	Map
CA	Palo Alto Medical Foundation-Fremont	Fremont94538	NCT07166406	Map
CA	City of Hope Seacliff	Huntington Beach92648	NCT07288034	Map
CA	City of Hope at Irvine Lennar	Irvine92618	NCT07288034	Map
CA	City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669	Irvine92618	NCT06109272	Map
CA	UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care	Irvine92612	NCT07166406	Map
CA	City of Hope Antelope Valley	Lancaster93534	NCT07288034	Map
CA	City of Hope at Long Beach Elm	Long Beach90813	NCT07288034	Map
CA	Cedars Sinai	Los Angeles90048	NCT07489976	Map
CA	Palo Alto Medical Foundation-Camino Division	Mountain View94040	NCT07166406	Map
CA	City of Hope at Newport Beach Fashion Island	Newport Beach92660	NCT07288034	Map
CA	UC Irvine /ID# 255673	Orange92868	NCT06109272	Map
CA	UC Irvine Health/Chao Family Comprehensive Cancer Center	Orange92868	NCT07166406	Map
CA	Palo Alto Medical Foundation Health Care	Palo Alto94301	NCT07166406	Map
CA	Research Site	Palo Alto94304	NCT06921785	Map
CA	Sutter Cancer Centers Radiation Oncology Services-Roseville	Roseville95661	NCT07166406	Map
CA	Sutter Roseville Medical Center	Roseville95661	NCT07166406	Map
CA	Sutter Medical Center Sacramento	Sacramento95816	NCT07166406	Map
CA	University of California Davis Comprehensive Cancer Center	Sacramento95817	NCT07166406	Map
CA	University of California, San Diego	San Diego92093	NCT06710223	Map
CA	California Pacific Medical Center-Pacific Campus	San Francisco94115	NCT07166406	Map
CA	University of California, San Francisco	San Francisco94143	NCT04430452	Map
CA	Sutter Pacific Medical Foundation	Santa Rosa95403	NCT07166406	Map
CA	City of Hope South Pasadena	South Pasadena91030	NCT07288034	Map
CA	Stanford University	Stanford94304	NCT04585490	Map
CA	Palo Alto Medical Foundation-Sunnyvale	Sunnyvale94086	NCT07166406	Map
CA	City of Hope South Bay	Torrance90503	NCT07288034	Map
CA	City of Hope Upland	Upland91786	NCT07288034	Map
CO	UCHealth University of Colorado Hospital	Aurora80045	NCT03606967	Map
CO	Cancer Care and Hematology-Fort Collins	Fort Collins80528	NCT07166406	Map
CO	Poudre Valley Hospital	Fort Collins80524	NCT07166406	Map
CO	Saint Mary's Hospital and Regional Medical Center	Grand Junction81501	NCT07166406	Map
CO	UCHealth Greeley Hospital	Greeley80631	NCT07166406	Map
CO	Medical Center of the Rockies	Loveland80538	NCT07166406	Map
CT	Smilow Cancer Hospital-Derby Care Center	Derby06418	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center-Fairfield	Fairfield06824	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center at Glastonbury	Glastonbury06033	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center at Greenwich	Greenwich06830	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center - Guilford	Guilford06437	NCT07166406	Map
CT	Smilow Cancer Hospital-Hamden Care Center	Hamden06518	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center at Saint Francis	Hartford06105	NCT07166406	Map
CT	Research Site	New Haven06520	NCT06921785	Map
CT	Smilow Cancer Center/Yale-New Haven Hospital	New Haven06510	NCT07166406	Map
CT	Yale University	New Haven06520	NCT07166406	Map
CT	Yale-New Haven Hospital North Haven Medical Center	North Haven06473	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center at Long Ridge	Stamford06902	NCT07166406	Map
CT	Smilow Cancer Hospital-Torrington Care Center	Torrington06790	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center-Trumbull	Trumbull06611	NCT07166406	Map
CT	Smilow Cancer Hospital-Waterbury Care Center	Waterbury06708	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center - Waterford	Waterford06385	NCT07166406	Map
DE	Research Site	Newark19713	NCT06921785	Map
DC	Georgetown Lombardi Comprehensive Cancer Center	Washington D.C.20007	NCT04499053	Map
DC	Medstar Washington Hospital Center	Washington D.C.20010	NCT04499053	Map
FL	UM Sylvester Comprehensive Cancer Center at Aventura	Aventura33180	NCT03606967	Map
FL	UM Sylvester Comprehensive Cancer Center at Coral Gables	Coral Gables33146	NCT03606967	Map
FL	UM Sylvester Comprehensive Cancer Center at Deerfield Beach	Deerfield Beach33442	NCT03606967	Map
FL	Mayo Clinic in Florida	Jacksonville32224-9980	NCT06058663	Map
FL	Research Site	Jacksonville32224	NCT06921785	Map
FL	UM Sylvester Comprehensive Cancer Center at Kendall	Miami33176	NCT03606967	Map
FL	University of Miami Miller School of Medicine-Sylvester Cancer Center	Miami33136	NCT03606967	Map
FL	UM Sylvester Comprehensive Cancer Center at Plantation	Plantation33324	NCT03606967	Map
FL	Moffitt Cancer Center	Tampa33612	NCT03606967	Map
FL	Moffitt Cancer Center - McKinley Campus	Tampa33612	NCT03606967	Map
FL	Moffitt Cancer Center-International Plaza	Tampa33607	NCT03606967	Map
FL	Moffitt Cancer Center at Wesley Chapel	Wesley Chapel33544	NCT03606967	Map
GA	Emory Proton Therapy Center	Atlanta30308	NCT07166406	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT07166406	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT07174570	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT07166406	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT07174570	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT07166406	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT07174570	Map
GA	Grady Health System	Atlanta30303	NCT07166406	Map
GA	Research Site	Atlanta30318	NCT06921785	Map
GA	City of Hope Atlanta Cancer Center	Newnan30265	NCT07288034	Map
IL	The University of Chicago Medical Center /ID# 255674	Chicago60637-1443	NCT06109272	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT07166406	Map
IL	UC Comprehensive Cancer Center at Silver Cross	New Lenox60451	NCT07166406	Map
IL	University of Chicago Medicine-Orland Park	Orland Park60462	NCT07166406	Map
IL	Memorial Hospital East	Shiloh62269	NCT07166406	Map
IL	City of Hope at Chicago	Zion60099	NCT07288034	Map
IN	UChicago Medicine Northwest Indiana	Crown Point46307	NCT07166406	Map
IN	Indiana University Melvin and Bren Simon Cancer Center	Indianapolis46202	NCT03317158	Map
IA	UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny50023	NCT07166406	Map
IA	Mercy Cancer Center-West Lakes	Clive50325	NCT07166406	Map
IA	UI Health Care Mission Cancer and Blood - West Des Moines Clinic	Clive50325	NCT07166406	Map
IA	Greater Regional Medical Center	Creston50801	NCT07166406	Map
IA	Iowa Methodist Medical Center	Des Moines50309	NCT07166406	Map
IA	Mercy Medical Center - Des Moines	Des Moines50314	NCT07166406	Map
IA	UI Health Care Mission Cancer and Blood - Des Moines Clinic	Des Moines50309	NCT07166406	Map
IA	UI Health Care Mission Cancer and Blood - Laurel Clinic	Des Moines50314	NCT07166406	Map
IA	University of Iowa Hospitals and Clinics	Iowa City52242	NCT03317158	Map
IA	UI Health Care Mission Cancer and Blood - Waukee Clinic	Waukee50263	NCT07166406	Map
IA	Mercy Medical Center-West Lakes	West Des Moines50266	NCT07166406	Map
IA	The Iowa Clinic PC	West Des Moines50266	NCT07166406	Map
KY	University of Kentucky/Markey Cancer Center	Lexington40536	NCT07166406	Map
KY	Norton Cancer Institute /ID# 260775	Louisville40217-1395	NCT06109272	Map
MD	Harry and Jeannette Weinberg Cancer Institute at Franklin Square	Baltimore21237	NCT04499053	Map
MD	Johns Hopkins	Baltimore21218	NCT07175441	Map
MD	Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center	Baltimore21231	NCT03317158	Map
MD	Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore21287	NCT03606967	Map
MD	Marlene and Stewart Greenebaum Comprehensive Cancer Center	Baltimore21201	NCT04499053	Map
MD	SKCCC Johns Hopkins Medical Institution	Baltimore21231	NCT06564623	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT05701488	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT05701488	Map
MI	Henry Ford Cancer Institute-Downriver	Brownstown48183	NCT07166406	—
MI	Henry Ford Medical Center-Fairlane	Dearborn48126	NCT07166406	Map
MI	Henry Ford Hospital	Detroit48202	NCT07166406	Map
MI	Henry Ford Hospital /ID# 255803	Detroit48202	NCT06109272	Map
MI	Research Site	Grand Rapids49503	NCT06921785	Map
MI	Allegiance Health	Jackson49201	NCT07166406	Map
MI	Henry Ford Medical Center-Columbus	Novi48377	NCT07166406	Map
MI	Henry Ford West Bloomfield Hospital	West Bloomfield48322	NCT07166406	Map
MI	Henry Ford Wyandotte Hospital	Wyandotte48192	NCT07166406	Map
MN	Essentia Health Saint Joseph's Medical Center	Brainerd56401	NCT07166406	Map
MN	Essentia Health - Deer River Clinic	Deer River56636	NCT07166406	Map
MN	Essentia Health Cancer Center	Duluth55805	NCT07166406	Map
MN	Essentia Health Saint Mary's Medical Center	Duluth55805	NCT07166406	Map
MN	Miller-Dwan Hospital	Duluth55805	NCT07166406	Map
MN	Essentia Health Hibbing Clinic	Hibbing55746	NCT07166406	Map
MN	Research Site	Rochester55905	NCT06921785	Map
MN	Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 256041	Saint Louis Park55416	NCT06109272	Map
MN	Essentia Health Sandstone	Sandstone55072	NCT07166406	Map
MN	Essentia Health Virginia Clinic	Virginia55792	NCT07166406	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT03606967	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT07166406	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT03606967	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT07166406	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT03606967	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT07166406	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT03606967	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT07166406	Map
MO	Washington University School of Medicine	St Louis63110	NCT03317158	Map
MO	Washington University School of Medicine	St Louis63110	NCT03606967	Map
MO	Washington University School of Medicine	St Louis63110	NCT07166406	Map
MO	Washington University-School of Medicine /ID# 255720	St Louis63110	NCT06109272	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT03317158	Map
NJ	Research Site	New Brunswick08901	NCT06921785	Map
NM	University of New Mexico Cancer Center	Albuquerque87106	NCT07166406	Map
NY	Columbia University Irving Medical Center	New York10032	NCT03317158	Map
NY	Mount Sinai Hospital	New York10029	NCT07166406	Map
NY	NYP/Weill Cornell Medical Center	New York10065	NCT03606967	Map
NY	Research Site	New York10029	NCT06921785	Map
NY	Montefiore Medical Center - Moses Campus	The Bronx10467	NCT07166406	Map
NY	Montefiore Medical Center-Einstein Campus	The Bronx10461	NCT07166406	Map
NC	Wake Forest University at Clemmons	Clemmons27012	NCT03606967	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT03606967	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT03606967	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT07166406	Map
OR	Clackamas Radiation Oncology Center	Clackamas97015	NCT07166406	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT07166406	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT07166406	Map
OR	OHSU Knight Cancer Institute	Portland97239	NCT04005690	Map
OR	Providence Portland Medical Center	Portland97213	NCT07166406	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT07166406	Map
PA	Geisinger Medical Center	Danville17822	NCT07166406	Map
PA	Geisinger Medical Oncology-Lewisburg	Lewisburg17837	NCT07166406	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT03317158	Map
PA	Research Site	Pittsburgh15232	NCT06921785	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT03606967	Map
PA	UPMC Hillman Cancer Center	Pittsburgh15232	NCT03539822	Map
PA	UPMC Hillman Cancer Center	Pittsburgh15232	NCT06698250	Map
PA	Geisinger Wyoming Valley/Henry Cancer Center	Wilkes-Barre18711	NCT07166406	Map
TN	Vanderbilt-Ingram Cancer Center	Nashville37232	NCT07175441	Map
TX	Texas Oncology - Abilene - Antilley Road /ID# 265820	Abilene79606	NCT06109272	Map
TX	Research Site	Amarillo79124	NCT06921785	Map
TX	Research Site	Austin78705	NCT06921785	Map
TX	Baylor Scott and White Research Institute /ID# 260853	Dallas76508-0001	NCT06109272	Map
TX	Texas Oncology - Dallas - Worth Street /ID# 265806	Dallas75246	NCT06109272	Map
TX	University of Texas Southwestern	Dallas75390	NCT07175441	Map
TX	START Dallas Fort Worth	Fort Worth76104	NCT07175441	Map
TX	University of Texas Medical Branch	Galveston77555-0565	NCT03606967	Map
TX	Baylor St Lukes	Houston77030	NCT05932199	Map
TX	Research Site	Houston77030	NCT06921785	Map
TX	Research Site	San Antonio78240	NCT06921785	Map
TX	UT Health San Antonio	San Antonio78229	NCT06526104	Map
TX	Research Site	Tyler75702	NCT06921785	Map
VA	Inova Alexandria Hospital	Alexandria22304	NCT07166406	Map
VA	Research Site	Arlington22201	NCT06921785	Map
VA	Inova Fair Oaks Hospital	Fairfax22033	NCT07166406	Map
VA	Inova Schar Cancer Institute	Fairfax22031	NCT07166406	Map
VA	Inova Fairfax Hospital	Falls Church22042	NCT07166406	Map
VA	Inova Loudoun Hospital	Leesburg20176	NCT07166406	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT03606967	Map
VA	Oncology and Hematology Associates of Southwest Virginia /ID# 265834	Roanoke98684	NCT06109272	Map
VA	Research Site	Salem24153	NCT06921785	Map
WI	Duluth Clinic Ashland	Ashland54806	NCT07166406	Map
WI	Northwest Wisconsin Cancer Center	Ashland54806	NCT07166406	Map
WI	Marshfield Medical Center-EC Cancer Center	Eau Claire54701	NCT07166406	Map
WI	Essentia Health-Hayward Clinic	Hayward54843	NCT07166406	Map
WI	Marshfield Medical Center-Marshfield	Marshfield54449	NCT07166406	Map
WI	Research Site	Milwaukee53226	NCT06921785	Map
WI	ProHealth D N Greenwald Center	Mukwonago53149	NCT07166406	Map
WI	ProHealth Oconomowoc Memorial Hospital	Oconomowoc53066	NCT07166406	Map
WI	Marshfield Medical Center-Rice Lake	Rice Lake54868	NCT07166406	Map
WI	Essentia Health-Spooner Clinic	Spooner54801	NCT07166406	Map
WI	Marshfield Medical Center-River Region at Stevens Point	Stevens Point54482	NCT07166406	Map
WI	Essentia Health Saint Mary's Hospital - Superior	Superior54880	NCT07166406	Map
WI	UW Cancer Center at ProHealth Care	Waukesha53188	NCT07166406	Map
WI	Marshfield Medical Center - Weston	Weston54476	NCT07166406	Map

Tremelimumab clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	withdrawn	not yet recruiting	unknown	approved for marketing	Total
Early P1	1	1	2		1	1			6
P1	5	3	29	8	3				48
P1/P2	4	5	16	3	2		1		31
P2	23	23	44	8	9	3	12		122
P2/P3	2								2
P3	5	11	4						20
N/A		1	2				1	1	5

Recruiting Tremelimumab clinical trials (44)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT03288532	RAMPARTRenal Adjuvant MultiPle Arm Randomised Trial	P3	Renal Cell Carcinoma	1,750	Jul 2018
NCT06999694	Proton-STRIDEProton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC	P2	HCC - Hepatocellular Carcinoma	45	May 2025
NCT06999707	Photon-STRIDEPhoton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC	P2	HCC - Hepatocellular Carcinoma	45	May 2025
NCT06680739	SERPENTINESingle cEll pRofiling PErsistaNce To ImmuNothErapy	P2	Colorectal Cancer	60	Mar 2022
NCT03847649	A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies	P2	Cancer	60	Mar 2020
NCT07489976	IIT2025-03-YANG-LIFT-HCC	P2	Hepato Cellular Carcinoma	41	Apr 2026
NCT06904170	ALICEDurvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma	P2/P3	Hepatocellular Carcinoma	196	Nov 2025
NCT06109272	LIVIGNO-2A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)	P2/P3	Hepatocellular Carcinoma	660	Jan 2024
NCT06921785	ARTEMIDE-HCC01Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma	P3	Hepatocellular Carcinoma	1,220	May 2025
NCT07122089	IOSPHEREEvaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis	P2	Hepatocellular Carcinoma Non-resectable	80	Feb 2026
NCT05451043	BLOCKEDDurvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)	P2	Pancreatic Cancer	62	Jul 2023
NCT04430452	Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma	P2	Advanced Hepatocellular Carcinoma	21	Feb 2022
NCT03539822	CAMILLACabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies	P1/P2	Gastric Cancer	117	Oct 2018
NCT06564623	BTCTargeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)	P1	Biliary Tract Cancers	25	May 2025
NCT07166406	Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial	P3	Advanced Hepatocellular Carcinoma	226	Feb 2026
NCT06880523	SLIDE-HCCSTRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma	140	Oct 2025
NCT06058663	Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma	P1	Locally Advanced Intrahepatic Cholangiocarcinoma	16	Jun 2024
NCT07288034	LImmunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial	P2	Lung Non-Small Cell Carcinoma	535	Apr 2026
NCT06824363	ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu	Early P1	Solid Tumor, Adult	34	Apr 2026
NCT06911255	MEDI4736Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma	P1/P2	Hepatocellular Carcinoma (HCC)	24	Apr 2025
NCT06855225	A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma	P2	Combined Hepatocellular and Cholangiocarcinoma	29	May 2026
NCT05932199	Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma	P1/P2	Mesothelioma	52	Jul 2024
NCT07168668	EXEPECTPartial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment	P2	HCC	90	Sep 2025
NCT04585490	Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC	P3	Non Small Cell Lung Cancer	48	Aug 2021
NCT04005690	Targeted Pathway Inhibition in Patients With Pancreatic Cancer	Early P1	Locally Advanced Pancreatic Ductal Adenocarcinoma	90	Aug 2019
NCT04522544	Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC	P2	Hepatocellular Carcinoma Non-resectable	55	Dec 2020
NCT04499053	Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer	P2	Carcinoma, Non-Small Cell Lung	18	Dec 2020
NCT03317158	ADAPT-BLADDERModern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder	P1/P2	Urothelial Carcinoma	55	Nov 2017
NCT06526104	MEDI4736Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis	P2	Hepatocellular Carcinoma	32	Dec 2024
NCT07174570	Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer	P2	Advanced Hepatocellular Carcinoma	39	Jan 2026
NCT02029001	MOST plusAdapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment	P2	Malignant Solid Neoplasms	900	Mar 2014
NCT07175441	Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma	P2	Advanced Unresectable Hepatocellular Carcinoma	220	Apr 2026
NCT07391670	IMFINZI-subQA Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab	P1	Solid Tumours	40	Mar 2026
NCT07511504	Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma	P2	Locally Advanced Hepatocellular Carcinoma	40	Apr 2026
NCT06710223	Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab	P1	Hepatocellular Carcinoma	20	Jan 2025
NCT06698250	ZENOBIAZanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)	P2	Hepatocellular Carcinoma	40	Dec 2024
NCT05844046	MONTBLANCSequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients	P2	Hepatocellular Carcinoma	83	Apr 2023
NCT03606967	Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer	P2	Anatomic Stage IV Breast Cancer AJCC v8	70	Apr 2021
NCT04988945	TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma	P2	HCC	33	Dec 2020
NCT05440864	(NEOTOMA)Durvalumab and Tremelimumab in Resectable HCC	P2	Hepatocellular Carcinoma	28	Oct 2023
NCT05701488	SIRT With Tremelimumab and Durvalumab for Resectable HCC	P1	Resectable Hepatocellular Carcinoma	20	Apr 2023
NCT05809869	Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma	25	Feb 2023
NCT06341764	Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma	P2	Cholangiocarcinoma	38	Sep 2023
NCT05557838	TREMENDOUSStudy of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma	P3	Hepatocellular Carcinoma	210	Feb 2023

Tremelimumab clinical trials by indication

Hepatocellular Carcinoma (18)

NCT	Acronym	Phase	Status	Title
NCT06904170	ALICE	P2/P3	recruiting	Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
NCT06109272	LIVIGNO-2	P2/P3	recruiting	A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
NCT06921785	ARTEMIDE-HCC01	P3	recruiting	Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06880523	SLIDE-HCC	P2	recruiting	STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
NCT07081633	TREMENDOUS-2	P2	active not recruiting	Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
NCT06526104	MEDI4736	P2	recruiting	Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
NCT06710223	—	P1	recruiting	Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
NCT05063565	ROWAN	P2	active not recruiting	TheraSphere With Durvalumab and Tremelimumab for HCC
+ 10 more, see All trials below.

Colorectal Cancer (5)

NCT	Acronym	Phase	Status	Title
NCT06680739	SERPENTINE	P2	recruiting	Single cEll pRofiling PErsistaNce To ImmuNothErapy
NCT03802747	—	P1	withdrawn	Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
NCT03206073	—	P1/P2	completed	A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
NCT02870920	—	P2	completed	Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
NCT03101475	ILOC	P2	completed	Synergism of Immunomodulation and Tumor Ablation

Advanced Solid Tumors (5)

NCT	Acronym	Phase	Status	Title
NCT01938612	—	P1	completed	A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
NCT03089645	—	P1	completed	MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
NCT02261220	—	P1	completed	A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
NCT02301130	—	P1	completed	Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
NCT02205333	MEDI6469	P1/P2	terminated	A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

Advanced Hepatocellular Carcinoma (4)

NCT	Acronym	Phase	Status	Title
NCT04430452	—	P2	recruiting	Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
NCT07166406	—	P3	recruiting	Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT07174570	—	P2	recruiting	Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
NCT05883644	SIERRA	P3	active not recruiting	Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

Bladder Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT04073160	TRIO Bladder	P1	withdrawn	TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer
NCT03150836	—	P2	withdrawn	Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
NCT03472274	DUTRENEO	P2	completed	Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)
NCT05120622	Rideau	P1/P2	withdrawn	Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer

Head and Neck Squamous Cell Carcinoma (4)

NCT	Acronym	Phase	Status	Title
NCT03212469	ABIMMUNE	P1/P2	completed	A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
NCT03283605	—	P1/P2	active not recruiting	Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
NCT03450967	—	P2	unknown	Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC
NCT02643303	—	P1/P2	completed	A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

HCC - Hepatocellular Carcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT06999694	Proton-STRIDE	P2	recruiting	Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
NCT06999707	Photon-STRIDE	P2	recruiting	Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
NCT06045975	DUMELEP	P2	active not recruiting	Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure

Mesothelioma (3)

NCT	Acronym	Phase	Status	Title
NCT05932199	—	P1/P2	recruiting	Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
NCT03075527	—	P2	terminated	A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
NCT02592551	—	P2	completed	MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Renal Cell Carcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT03288532	RAMPART	P3	recruiting	Renal Adjuvant MultiPle Arm Randomised Trial
NCT03598816	PIVOT-RCC	P2	withdrawn	PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
NCT02762006	—	P1	completed	Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

Non-small Cell Lung Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT03965468	CHESS	P2	active not recruiting	Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
NCT03275597	SBRT	P1	terminated	Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition
NCT03130764	—	P2	withdrawn	Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

Urothelial Carcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT03317158	ADAPT-BLADDER	P1/P2	recruiting	Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT03871036	ICRA	P1/P2	completed	Improve Checkpoint-blockade Response in Advanced Urothelial Cancer
NCT03557918	—	P2	completed	Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

Squamous Cell Carcinoma of the Head and Neck (3)

NCT	Acronym	Phase	Status	Title
NCT03624231	DURTRE-RAD	P2	completed	Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC
NCT02551159	KESTREL	P3	completed	Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
NCT02262741	—	P1	completed	A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

Prostate Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT03385655	—	P2	active not recruiting	Prostate Cancer Biomarker Enrichment and Treatment Selection
NCT02788773	—	P2	completed	Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
NCT00702923	CP-675	P1	terminated	CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

Hepatocellular Carcinoma Non-resectable (2)

NCT	Acronym	Phase	Status	Title
NCT07122089	IOSPHERE	P2	recruiting	Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis
NCT04522544	—	P2	recruiting	Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Hepatocellular Carcinoma (HCC) (2)

NCT	Acronym	Phase	Status	Title
NCT06994299	PRISM	P2	withdrawn	A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma
NCT06911255	MEDI4736	P1/P2	recruiting	Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

HCC (2)

NCT	Acronym	Phase	Status	Title
NCT07168668	EXEPECT	P2	not yet recruiting	Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment
NCT04988945	—	P2	recruiting	TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

Carcinoma, Non-Small-Cell Lung (2)

NCT	Acronym	Phase	Status	Title
NCT06008093	TRITON	P2	active not recruiting	A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
NCT03975114	MILES-5	P2	unknown	A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)

Unresectable Hepatocellular Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT06117891	REFINE-IO	N/A	active not recruiting	An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
NCT05345678	—	N/A	approved for marketing	Himalaya Early Access Program

Cholangiocarcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT06341764	—	P2	recruiting	Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma
NCT03473574	IMMUCHEC	P2	completed	Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

Pancreatic Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT05451043	BLOCKED	P2	recruiting	Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
NCT02868632	—	P1	withdrawn	Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Non Small Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT04585490	—	P3	recruiting	Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
NCT02040064	GEFTREM	P1	completed	Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients

Gastric Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT03539822	CAMILLA	P1/P2	recruiting	Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
NCT04817826	INFINITY	P2	active not recruiting	TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.

Metastatic Colorectal Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT03982173	MATILDA	P2	withdrawn	Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
NCT03122509	—	P2	completed	A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

Small Cell Lung Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT03963414	—	P1	terminated	A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
NCT02658214	—	P1	completed	Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT03847649	—	P2	recruiting	A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
NCT02938793	—	P2	terminated	Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Esophageal Adenocarcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT02962063	—	P1/P2	active not recruiting	Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
NCT04159974	RICE	P2	unknown	RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus

Recurrent Squamous Cell Lung Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT02154490	—	N/A	completed	Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
NCT03373760	—	P2	completed	Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Ovarian Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT02571725	—	P1/P2	active not recruiting	PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
NCT03249142	INeOV	P1/P2	completed	Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer

Metastatic Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT03608865	MEDI4736	P2	completed	Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing
NCT02563925	—	N/A	completed	Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

HNSCC (2)

NCT	Acronym	Phase	Status	Title
NCT03292250	TRIUMPH	P2	completed	Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
NCT06446570	MEDI4736	P2	completed	Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

Colorectal Cancer Metastatic (2)

NCT	Acronym	Phase	Status	Title
NCT03202758	MEDITREME	P1/P2	completed	Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC
NCT03007407	—	P2	completed	Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy

Metastatic Carcinoma in the Liver (2)

NCT	Acronym	Phase	Status	Title
NCT02754856	—	P1	completed	Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
NCT03005002	—	P1	completed	Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT01975831	—	P1	completed	A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
NCT03430466	—	P2	terminated	Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Germ Cell Tumor (2)

NCT	Acronym	Phase	Status	Title
NCT03158064	MEDI4736	P2	active not recruiting	Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
NCT03081923	APACHE	P2	terminated	Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors

Biliary Tract Neoplasms (2)

NCT	Acronym	Phase	Status	Title
NCT03046862	MEDI4736	P2	unknown	Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer
NCT02821754	HCC	P2	completed	A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Malignant Mesothelioma (2)

NCT	Acronym	Phase	Status	Title
NCT01655888	—	P2	unknown	The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma
NCT01649024	—	P2	unknown	A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

Combined Hepatocellular and Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06855225	—	P2	not yet recruiting	A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Solid Tumor, Adult (1)

NCT	Acronym	Phase	Status	Title
NCT06824363	—	Early P1	not yet recruiting	ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

Advanced Unresectable Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07175441	—	P2	recruiting	Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

Lung Non-Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07288034	L	P2	recruiting	Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Locally Advanced Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07511504	—	P2	not yet recruiting	Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

Hepato Cellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07489976	—	P2	recruiting	IIT2025-03-YANG-LIFT-HCC

Solid Tumours (1)

NCT	Acronym	Phase	Status	Title
NCT07391670	IMFINZI-subQ	P1	recruiting	A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab

Hepato Cellular Carcinoma (HCC) (1)

NCT	Acronym	Phase	Status	Title
NCT06608940	STRIDE	P1/P2	withdrawn	BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Biliary Tract Cancers (1)

NCT	Acronym	Phase	Status	Title
NCT06564623	BTC	P1	recruiting	Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Borderline Resectable Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06017297	ESR-22-21719	P2	withdrawn	Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

Locally Advanced Intrahepatic Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06058663	—	P1	recruiting	Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Unrescetable Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05864755	—	P2	unknown	HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05701488	—	P1	recruiting	SIRT With Tremelimumab and Durvalumab for Resectable HCC

Nonsmall Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04625699	—	P2	withdrawn	Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Biliary Tract Cancer (CCA) (1)

NCT	Acronym	Phase	Status	Title
NCT05239169	—	P2	completed	Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

NSCLC Stage IV (1)

NCT	Acronym	Phase	Status	Title
NCT05383001	—	P2	withdrawn	Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Mesothelioma, Malignant (1)

NCT	Acronym	Phase	Status	Title
NCT05380713	—	P2	completed	......SMARTEST Trial......

Metastatic or Locally Advanced NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT05000710	CORAL-Lung	P2	active not recruiting	Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

Muscle Invasive Bladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04960709	VOLGA	P3	active not recruiting	Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

BCLC Stage B Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04605731	—	P1	active not recruiting	Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Anatomic Stage IV Breast Cancer AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT03606967	—	P2	recruiting	Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Hepatocellular Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03937830	TACE	P2	active not recruiting	Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Carcinoma, Non-Small Cell Lung (1)

NCT	Acronym	Phase	Status	Title
NCT04499053	—	P2	recruiting	Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Malignant Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT04223648	MEDI4736	Early P1	withdrawn	Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Metastatic Malignant Female Reproductive System Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT04395079	—	P2	active not recruiting	Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT04107168	—	N/A	unknown	Microbiome Immunotherapy Toxicity and Response Evaluation

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04221555	—	P2	completed	Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Pancreatic Cancer Non-resectable (1)

NCT	Acronym	Phase	Status	Title
NCT04156087	MIMIPAC	P2	completed	Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer

Immunotherapy (1)

NCT	Acronym	Phase	Status	Title
NCT04169841	GUIDE2REPAIR	P2	active not recruiting	Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

Fallopian Tube Endometrioid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT04034927	—	P2	active not recruiting	Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Intrahepatic Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04238637	BTC	P2	active not recruiting	Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Intermediate Stage of Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03638141	DEB-TACE	P2	completed	CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Locally Advanced Pancreatic Ductal Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04005690	—	Early P1	recruiting	Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Gastric Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03959293	—	P2	active not recruiting	Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Ovarian Cancer Stage IIIC (1)

NCT	Acronym	Phase	Status	Title
NCT03899610	KGOG3046	P2	unknown	A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)

Tumor, Solid (1)

NCT	Acronym	Phase	Status	Title
NCT03911557	—	P2	completed	Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Small Cell Lung Cancer Extensive Stage (1)

NCT	Acronym	Phase	Status	Title
NCT03923270	—	P1	active not recruiting	Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Metastatic Thyroid Papillary Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03753919	DUTHY	P2	terminated	Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

Recurrent Lung Non-Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03581487	—	P1/P2	completed	Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Pediatric Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03837899	—	P1/P2	active not recruiting	Durvalumab and Tremelimumab for Pediatric Malignancies

Stage II-IVB Operable HNSCC Oral Cavity (1)

NCT	Acronym	Phase	Status	Title
NCT03737968	MEDI4736	P2	unknown	Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Stage III NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT04287894	Induction	P1	terminated	Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

Infiltrating Bladder Urothelial Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03549715	NEMIO	P1/P2	unknown	NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma

Platinum-resistant Recurrent Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03699449	AMBITION	P2	unknown	An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT03693612	—	P1/P2	completed	GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Invasive Bladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03702179	IMMUNOPRESERVE	P2	completed	Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach

Advanced Biliary Tract Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03704480	IMMUNO-BIL	P2	active not recruiting	Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.

Squamous Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03319316	SOLUTION	P2	withdrawn	Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)

Bladder Urothelial Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03601455	—	P2	active not recruiting	Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

EGFR Mutant Advanced Non Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03994393	ILLUMINATE	P2	unknown	Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8 (1)

NCT	Acronym	Phase	Status	Title
NCT03618134	—	P1/P2	terminated	Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Unresectable Locally Advanced Urothelial Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03682068	NILE	P3	active not recruiting	Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03703297	ADRIATIC	P3	active not recruiting	Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Locally Advanced Head and Neck Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03426657	—	P2	completed	Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC

Oral Cavity Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03784066	DUTRELASCO	P1/P2	active not recruiting	Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity

Advanced Cervical Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03452332	—	P1	completed	Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

Muscle-invasive Bladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03234153	NITIMIB	P2	terminated	Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin

Advanced Solid Tumours (1)

NCT	Acronym	Phase	Status	Title
NCT03518606	MOVIE	P1/P2	completed	Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours

Metastatic Gastric Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03751761	MEDI4736	P1/P2	completed	GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Recurrent Gynecological Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03277482	—	P1	terminated	Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Oropharyngeal Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03410615	—	P2	active not recruiting	Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Metastatic Head and Neck Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03522584	—	P1/P2	terminated	Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Carcinoma, Squamous Cell of Head and Neck (1)

NCT	Acronym	Phase	Status	Title
NCT03509012	CLOVER	P1	completed	Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Non-Transitional Cell Carcinoma of the Urothelial Tract (1)

NCT	Acronym	Phase	Status	Title
NCT03430895	MEDI4736	P2	completed	Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Metastatic Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03164772	—	P1/P2	completed	Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

Metastatic Adult Soft Tissue Sarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT03317457	MEDISARC	P2	completed	Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Extensive-stage Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03085849	—	P1	completed	SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03237377	—	P2	terminated	Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Metastatic Colorectal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02888743	—	P2	active not recruiting	Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Castration-Resistant Prostate Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03204812	—	P2	completed	Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7 (1)

NCT	Acronym	Phase	Status	Title
NCT03144778	—	P1	completed	Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

BRCA1 Gene Mutation (1)

NCT	Acronym	Phase	Status	Title
NCT02953457	—	P2	completed	Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Anatomic Stage II Breast Cancer AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT03132467	—	Early P1	completed	Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Advanced Solid Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT03084471	STRONG	P3	completed	An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

Non Small Cell Lung Cancer NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT03164616	POSEIDON	P3	active not recruiting	Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT03022500	—	P2	completed	Pulmonary sarcomatoid_MEDI4736+Treme

Platinum-Resistant Fallopian Tube Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03026062	—	P2	completed	Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Metastatic Anaplastic Thyroid Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03122496	SBRT	P1	completed	Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Neuroendocrine Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT03095274	DUNE	P2	completed	Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin

Lung Cancer Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT03057106	—	P2	active not recruiting	Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Small Cell Lung Carcinoma Extensive Disease (1)

NCT	Acronym	Phase	Status	Title
NCT03043872	CASPIAN	P3	active not recruiting	Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

Head and Neck Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03019003	ASTX727	P1	completed	Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Hydronephrosis (1)

NCT	Acronym	Phase	Status	Title
NCT02812420	—	Early P1	active not recruiting	Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Endometrial Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03015129	—	P2	completed	A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Advanced Rare Tumours (1)

NCT	Acronym	Phase	Status	Title
NCT02879162	—	P2	completed	Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT02716805	—	P1	terminated	Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Advanced Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT02978482	MEDI4736	P1	completed	A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02937818	—	P2	completed	A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Pancreatic Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02879318	—	P2	completed	Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Malignant Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT02794883	—	P2	completed	Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

Advanced and/or Metastatic Sarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT02815995	—	P2	completed	Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Diffuse Large B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02549651	D4190C00023	P1	completed	MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Esophageal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02735239	—	P1/P2	completed	Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT02718911	—	P1	completed	A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Renal Clear Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02819596	CALYPSO	P2	completed	MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

Recurrent Small Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02701400	—	P2	completed	Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

Select Advanced Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT02705482	—	P1	completed	A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Clear Cell Renal Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02626130	—	Early P1	completed	Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer

Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT02639026	—	P1	completed	Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Estrogen Receptor Negative (1)

NCT	Acronym	Phase	Status	Title
NCT02536794	—	P2	completed	MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

Primary Peritoneal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02485990	—	P1	terminated	Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)

Prostatic Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT02616185	—	P1	terminated	A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02586987	—	P1	completed	A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Metastatic Pancreatic Ductal Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02558894	—	P2	completed	Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

Non Small Cell Lung Carcinoma NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT02542293	NEPTUNE	P3	active not recruiting	Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

Urothelial Bladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02527434	—	P2	completed	Study of Tremelimumab in Patients With Advanced Solid Tumors

Urothelial Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02516241	—	P3	active not recruiting	Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Pleural Mesothelioma (1)

NCT	Acronym	Phase	Status	Title
NCT02588131	NIBIT-MESO-1	P2	unknown	A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

Solid Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT02537418	—	P1	active not recruiting	Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN (1)

NCT	Acronym	Phase	Status	Title
NCT02369874	EAGLE	P3	completed	Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck (1)

NCT	Acronym	Phase	Status	Title
NCT02499328	—	P1/P2	completed	Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Non-Small-Cell Lung Carcinoma NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT02453282	MYSTIC	P3	active not recruiting	Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck (1)

NCT	Acronym	Phase	Status	Title
NCT02319044	—	P2	completed	Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Gastric or Gastroesophageal Junction Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02340975	—	P1/P2	completed	A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

Pancreatic Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT02311361	—	P1/P2	completed	Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Non - Small Cell Lung Cancer NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT02352948	ARCTIC	P3	completed	A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV) (1)

NCT	Acronym	Phase	Status	Title
NCT02179671	MEDI4736	P2	completed	Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Metastatic Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT02141542	—	P1	completed	Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Part A and B: Advanced Solid Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT02141347	—	P1	completed	Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Myelodysplastic Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT02117219	—	P1	completed	Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Malignant Solid Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT02029001	MOST plus	P2	recruiting	Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT02000947	D4190C00006	P1	completed	A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

Unresectable Pleural or Peritoneal Malignant Mesothelioma (1)

NCT	Acronym	Phase	Status	Title
NCT01843374	Tremelimumab	P2	active not recruiting	Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Heptocellular Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01853618	—	P1/P2	completed	Tremelimumab With Chemoembolization or Ablation for Liver Cancer

Cutaneous Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT04274816	—	P1	completed	Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

Recurrent Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT01103635	—	P1	completed	Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Colorectal Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT00378482	—	P2	completed	A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Tremelimumab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
RAMPART	NCT03288532	P3	recruiting	Renal Cell Carcinoma	1,750	PMID 34538402
ARTEMIDE-HCC01	NCT06921785	P3	recruiting	Hepatocellular Carcinoma	1,220	—
VOLGA	NCT04960709	P3	active not recruiting	Muscle Invasive Bladder Cancer	712	—
POSEIDON	NCT03164616	P3	active not recruiting	Non Small Cell Lung Cancer NSCLC	1,186	PMID 39243945
NILE	NCT03682068	P3	active not recruiting	Unresectable Locally Advanced Urothelial Cancer	1,246	—
EMERALD-3	NCT05301842	P3	active not recruiting	Hepatocellular Carcinoma	760	—
CASPIAN	NCT03043872	P3	active not recruiting	Small Cell Lung Carcinoma Extensive Disease	987	PMID 38811992
NEPTUNE	NCT02542293	P3	active not recruiting	Non Small Cell Lung Carcinoma NSCLC	953	PMID 36806898
MYSTIC	NCT02453282	P3	active not recruiting	Non-Small-Cell Lung Carcinoma NSCLC	1,118	PMID 32271377
ADRIATIC	NCT03703297	P3	active not recruiting	Small Cell Lung Cancer	730	PMID 40976711
SIERRA	NCT05883644	P3	active not recruiting	Advanced Hepatocellular Carcinoma	111	—
HIMALAYA	NCT03298451	P3	active not recruiting	Hepatocellular Carcinoma	1,324	PMID 38805668
TREMENDOUS	NCT05557838	P3	recruiting	Hepatocellular Carcinoma	210	—
ARCTIC	NCT02352948	P3	completed	Non - Small Cell Lung Cancer NSCLC	597	PMID 32201234
STRONG	NCT03084471	P3	completed	Advanced Solid Malignancies	867	PMID 35042068
KESTREL	NCT02551159	P3	completed	Squamous Cell Carcinoma of the Head and Neck	823	PMID 38430375
EAGLE	NCT02369874	P3	completed	Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN	736	PMID 32294530
Proton-STRIDE	NCT06999694	P2	recruiting	HCC - Hepatocellular Carcinoma	45	—
Photon-STRIDE	NCT06999707	P2	recruiting	HCC - Hepatocellular Carcinoma	45	—
SERPENTINE	NCT06680739	P2	recruiting	Colorectal Cancer	60	—
IOSPHERE	NCT07122089	P2	recruiting	Hepatocellular Carcinoma Non-resectable	80	—
BLOCKED	NCT05451043	P2	recruiting	Pancreatic Cancer	62	—
SLIDE-HCC	NCT06880523	P2	recruiting	Hepatocellular Carcinoma	140	—
TREMENDOUS-2	NCT07081633	P2	active not recruiting	Hepatocellular Carcinoma	114	—
L	NCT07288034	P2	recruiting	Lung Non-Small Cell Carcinoma	535	—
DUMELEP	NCT06045975	P2	active not recruiting	HCC - Hepatocellular Carcinoma	30	PMID 20060829
PRISM	NCT06994299	P2	withdrawn	Hepatocellular Carcinoma (HCC)	0	—
EXEPECT	NCT07168668	P2	not yet recruiting	HCC	90	—
TACE	NCT03937830	P2	active not recruiting	Hepatocellular Cancer	27	—
BTC	NCT04238637	P2	active not recruiting	Intrahepatic Cholangiocarcinoma	50	—
TRITON	NCT06008093	P2	active not recruiting	Carcinoma, Non-Small-Cell Lung	100	PMID 41209621
MEDI4736	NCT06526104	P2	recruiting	Hepatocellular Carcinoma	32	—
MOST plus	NCT02029001	P2	recruiting	Malignant Solid Neoplasms	900	PMID 37444551
GUIDE2REPAIR	NCT04169841	P2	active not recruiting	Immunotherapy	270	PMID 32778095
ROWAN	NCT05063565	P2	active not recruiting	Hepatocellular Carcinoma	100	—
ZENOBIA	NCT06698250	P2	recruiting	Hepatocellular Carcinoma	40	—
MONTBLANC	NCT05844046	P2	recruiting	Hepatocellular Carcinoma	83	PMID 41732658
CORAL-Lung	NCT05000710	P2	active not recruiting	Metastatic or Locally Advanced NSCLC	29	PMID 26541610
CHESS	NCT03965468	P2	active not recruiting	Non-small Cell Lung Cancer	96	PMID 21423255
ESR-22-21719	NCT06017297	P2	withdrawn	Borderline Resectable Carcinoma	0	—
(NEOTOMA)	NCT05440864	P2	recruiting	Hepatocellular Carcinoma	28	PMID 18841514
MEDI4736	NCT03158064	P2	active not recruiting	Germ Cell Tumor	30	—
Tremelimumab	NCT01843374	P2	active not recruiting	Unresectable Pleural or Peritoneal Malignant Mesothelioma	571	PMID 28729154
INFINITY	NCT04817826	P2	active not recruiting	Gastric Cancer	31	PMID 40340830
MEDI4736	NCT03482102	P2	active not recruiting	Hepatocellular Carcinoma	37	—
IMMUNO-BIL	NCT03704480	P2	active not recruiting	Advanced Biliary Tract Carcinoma	106	PMID 33279854
MEDI4736	NCT03046862	P2	unknown	Biliary Tract Neoplasms	31	PMID 35278356
MATILDA	NCT03982173	P2	withdrawn	Metastatic Colorectal Cancer	0	—
DUTHY	NCT03753919	P2	terminated	Metastatic Thyroid Papillary Carcinoma	79	PMID 41935063
MEDI4736	NCT05027425	P2	terminated	Hepatocellular Carcinoma	8	—
DEB-TACE	NCT03638141	P2	completed	Intermediate Stage of Hepatocellular Carcinoma	21	—
CALYPSO	NCT02819596	P2	completed	Renal Clear Cell Carcinoma	69	PMID 36809050
RICE	NCT04159974	P2	unknown	Esophageal Adenocarcinoma	56	—
MILES-5	NCT03975114	P2	unknown	Carcinoma, Non-Small-Cell Lung	460	—
PIVOT-RCC	NCT03598816	P2	withdrawn	Renal Cell Carcinoma	0	—
ILLUMINATE	NCT03994393	P2	unknown	EGFR Mutant Advanced Non Small Cell Lung Cancer	100	PMID 39877028
MIMIPAC	NCT04156087	P2	completed	Pancreatic Cancer Non-resectable	12	—
MEDI4736	NCT03737968	P2	unknown	Stage II-IVB Operable HNSCC Oral Cavity	48	PMID 38857913
DURTRE-RAD	NCT03624231	P2	completed	Squamous Cell Carcinoma of the Head and Neck	18	—
DUTRENEO	NCT03472274	P2	completed	Bladder Cancer	101	PMID 39864059
HCC	NCT02821754	P2	completed	Biliary Tract Neoplasms	54	PMID 39965889
SOLUTION	NCT03319316	P2	withdrawn	Squamous Non-small Cell Lung Cancer	0	—
AMBITION	NCT03699449	P2	unknown	Platinum-resistant Recurrent Ovarian Cancer	104	PMID 31671191
IMMUNOPRESERVE	NCT03702179	P2	completed	Invasive Bladder Cancer	32	—
MEDISARC	NCT03317457	P2	completed	Metastatic Adult Soft Tissue Sarcoma	103	—
DUNE	NCT03095274	P2	completed	Neuroendocrine Tumors	126	PMID 37221181
IMMUCHEC	NCT03473574	P2	completed	Cholangiocarcinoma	128	—
TRIUMPH	NCT03292250	P2	completed	HNSCC	180	PMID 37699162
ILOC	NCT03101475	P2	completed	Colorectal Cancer	22	—
MEDI4736	NCT03608865	P2	completed	Metastatic Breast Cancer	30	—
MEDI4736	NCT06446570	P2	completed	HNSCC	18	—
KGOG3046	NCT03899610	P2	unknown	Ovarian Cancer Stage IIIC	24	PMID 37865397
MEDI4736	NCT03430895	P2	completed	Non-Transitional Cell Carcinoma of the Urothelial Tract	15	—
NITIMIB	NCT03234153	P2	terminated	Muscle-invasive Bladder Cancer	6	—
APACHE	NCT03081923	P2	terminated	Germ Cell Tumor	36	PMID 30243800
NIBIT-MESO-1	NCT02588131	P2	unknown	Pleural Mesothelioma	40	PMID 33844995
MEDI4736	NCT02179671	P2	completed	Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)	32	—

Terminated and withdrawn Tremelimumab trials (34)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT06994299withdrawnA Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma
NCT06608940withdrawnBC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
NCT06017297withdrawnNeoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma
NCT05383001withdrawnRandomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)
NCT04073160withdrawnTRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer
NCT02938793terminatedDurvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
NCT04223648withdrawnProgrammed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
NCT03802747withdrawnImmunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
NCT03075527terminatedA Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
NCT03982173withdrawnBasket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
NCT03753919terminatedDurvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
NCT05027425terminatedDurvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
NCT04287894terminatedAssess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
NCT03150836withdrawnRadiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
NCT03598816withdrawnPolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
NCT03237377terminatedNeoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer
NCT04625699withdrawnStudy of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
NCT03618134terminatedStereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
NCT03319316withdrawnCombination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
NCT03277482terminatedDurvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
NCT05120622withdrawnTrial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer
NCT03522584terminatedDurvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT03963414terminatedA Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
NCT02616185terminatedA Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
NCT03275597terminatedPhase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition
NCT03234153terminatedNeoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin
NCT02485990terminatedStudy of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
NCT03081923terminatedDurvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors
NCT02868632withdrawnStudy of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
NCT03430466terminatedAnti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer
NCT02716805terminatedPhase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
NCT03130764withdrawnDurvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
NCT02205333terminatedA Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
NCT00702923terminatedCP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

All Tremelimumab trials (234)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT03288532	RAMPART	Renal Adjuvant MultiPle Arm Randomised Trial	P3	recruiting	1,750	University College, London	Jul 2018
NCT06999694	Proton-STRIDE	Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC	P2	recruiting	45	Chang Gung Memorial Hospital	May 2025
NCT06999707	Photon-STRIDE	Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC	P2	recruiting	45	Chang Gung Memorial Hospital	May 2025
NCT06680739	SERPENTINE	Single cEll pRofiling PErsistaNce To ImmuNothErapy	P2	recruiting	60	Vall d'Hebron Institute of Oncology	Mar 2022
NCT03847649		A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies	P2	recruiting	60	Canadian Cancer Trials Group	Mar 2020
NCT07489976		IIT2025-03-YANG-LIFT-HCC	P2	recruiting	41	Ju Dong Yang	Apr 2026
NCT06904170	ALICE	Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma	P2/P3	recruiting	196	UNICANCER	Nov 2025
NCT06109272	LIVIGNO-2	A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)	P2/P3	recruiting	660	AbbVie	Jan 2024
NCT06921785	ARTEMIDE-HCC01	Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma	P3	recruiting	1,220	AstraZeneca	May 2025
NCT07122089	IOSPHERE	Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis	P2	recruiting	80	Center Eugene Marquis	Feb 2026
NCT05451043	BLOCKED	Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)	P2	recruiting	62	AHS Cancer Control Alberta	Jul 2023
NCT04430452		Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma	P2	recruiting	21	Mary Feng, MD	Feb 2022
NCT03539822	CAMILLA	Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies	P1/P2	recruiting	117	Anwaar Saeed	Oct 2018
NCT06564623	BTC	Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)	P1	recruiting	25	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	May 2025
NCT07166406		Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial	P3	recruiting	226	NRG Oncology	Feb 2026
NCT06880523	SLIDE-HCC	STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma	P2	recruiting	140	Canadian Cancer Trials Group	Oct 2025
NCT07081633	TREMENDOUS-2	Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma	P2	active not recruiting	114	AstraZeneca	Aug 2025
NCT06058663		Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma	P1	recruiting	16	Mayo Clinic	Jun 2024
NCT07288034	L	Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial	P2	recruiting	535	City of Hope Medical Center	Apr 2026
NCT06045975	DUMELEP	Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure	P2	active not recruiting	30	Assistance Publique - Hôpitaux de Paris	Mar 2024
NCT04960709	VOLGA	Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin	P3	active not recruiting	712	AstraZeneca	Aug 2021
NCT06824363		ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu	Early P1	not yet recruiting	34	University of California, Irvine	Apr 2026
NCT06994299	PRISM	A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma	P2	withdrawn	0	Weill Medical College of Cornell University	Oct 2025
NCT06911255	MEDI4736	Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma	P1/P2	recruiting	24	Yoon Jun Kim	Apr 2025
NCT06855225		A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma	P2	not yet recruiting	29	Mehmet Akce	May 2026
NCT05932199		Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma	P1/P2	recruiting	52	Baylor College of Medicine	Jul 2024
NCT07168668	EXEPECT	Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment	P2	not yet recruiting	90	Chang Gung Memorial Hospital	Sep 2025
NCT04585490		Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC	P3	recruiting	48	Maximilian Diehn	Aug 2021
NCT04005690		Targeted Pathway Inhibition in Patients With Pancreatic Cancer	Early P1	recruiting	90	OHSU Knight Cancer Institute	Aug 2019
NCT03601455		Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer	P2	active not recruiting	13	Jonsson Comprehensive Cancer Center	Oct 2018
NCT06608940	STRIDE	BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma	P1/P2	withdrawn	0	Case Comprehensive Cancer Center	Nov 2025
NCT03937830	TACE	Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma	P2	active not recruiting	27	National Cancer Institute (NCI)	Mar 2021
NCT04522544		Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC	P2	recruiting	55	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Dec 2020
NCT04499053		Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer	P2	recruiting	18	Georgetown University	Dec 2020
NCT04238637	BTC	Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)	P2	active not recruiting	50	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Nov 2019
NCT03317158	ADAPT-BLADDER	Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder	P1/P2	recruiting	55	Noah Hahn, M.D.	Nov 2017
NCT02812420		Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery	Early P1	active not recruiting	54	M.D. Anderson Cancer Center	Mar 2017
NCT06008093	TRITON	A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS	P2	active not recruiting	100	AstraZeneca	Apr 2024
NCT06526104	MEDI4736	Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis	P2	recruiting	32	The University of Texas Health Science Center at San Antonio	Dec 2024
NCT03164616	POSEIDON	Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).	P3	active not recruiting	1,186	AstraZeneca	Jun 2017
NCT07174570		Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer	P2	recruiting	39	Emory University	Jan 2026
NCT02029001	MOST plus	Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment	P2	recruiting	900	Centre Leon Berard	Mar 2014
NCT07175441		Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma	P2	recruiting	220	Riboscience, LLC.	Apr 2026
NCT07391670	IMFINZI-subQ	A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab	P1	recruiting	40	AstraZeneca	Mar 2026
NCT04169841	GUIDE2REPAIR	Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	P2	active not recruiting	270	Centre Georges Francois Leclerc	Feb 2020
NCT07511504		Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma	P2	not yet recruiting	40	OHSU Knight Cancer Institute	Apr 2026
NCT02571725		PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer	P1/P2	active not recruiting	50	New Mexico Cancer Research Alliance	Feb 2016
NCT06710223		Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab	P1	recruiting	20	University of California, San Diego	Jan 2025
NCT05063565	ROWAN	TheraSphere With Durvalumab and Tremelimumab for HCC	P2	active not recruiting	100	Boston Scientific Corporation	Nov 2023
NCT03682068	NILE	Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer	P3	active not recruiting	1,246	AstraZeneca	Sep 2018
NCT06698250	ZENOBIA	Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)	P2	recruiting	40	Anwaar Saeed	Dec 2024
NCT05301842	EMERALD-3	Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC	P3	active not recruiting	760	AstraZeneca	Mar 2022
NCT04605731		Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer	P1	active not recruiting	25	City of Hope Medical Center	Aug 2021
NCT04034927		Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer	P2	active not recruiting	61	National Cancer Institute (NCI)	Dec 2019
NCT02888743		Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer	P2	active not recruiting	110	National Cancer Institute (NCI)	Aug 2017
NCT05844046	MONTBLANC	Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients	P2	recruiting	83	Enrico De Toni	Apr 2023
NCT05000710	CORAL-Lung	Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy	P2	active not recruiting	29	Sheba Medical Center	Dec 2021
NCT03965468	CHESS	Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC	P2	active not recruiting	96	ETOP IBCSG Partners Foundation	Nov 2019
NCT03923270		Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer	P1	active not recruiting	25	H. Lee Moffitt Cancer Center and Research Institute	Jun 2019
NCT03837899		Durvalumab and Tremelimumab for Pediatric Malignancies	P1/P2	active not recruiting	50	AstraZeneca	Mar 2019
NCT03043872	CASPIAN	Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)	P3	active not recruiting	987	AstraZeneca	Mar 2017
NCT02542293	NEPTUNE	Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)	P3	active not recruiting	953	AstraZeneca	Nov 2015
NCT02516241		Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer	P3	active not recruiting	1,126	AstraZeneca	Nov 2015
NCT02537418		Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens	P1	active not recruiting	153	Canadian Cancer Trials Group	Oct 2015
NCT02453282	MYSTIC	Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)	P3	active not recruiting	1,118	AstraZeneca	Jul 2015
NCT03606967		Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer	P2	recruiting	70	National Cancer Institute (NCI)	Apr 2021
NCT02519348		A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma	P2	active not recruiting	433	MedImmune LLC	Oct 2015
NCT06117891	REFINE-IO	An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery	—	active not recruiting	300	Bayer	Nov 2023
NCT04988945		TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma	P2	recruiting	33	The University of Hong Kong	Dec 2020
NCT04395079		Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies	P2	active not recruiting	9	Jonsson Comprehensive Cancer Center	Aug 2020
NCT06017297	ESR-22-21719	Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma	P2	withdrawn	0	Georgetown University	Dec 2024
NCT05440864	(NEOTOMA)	Durvalumab and Tremelimumab in Resectable HCC	P2	recruiting	28	University Health Network, Toronto	Oct 2023
NCT03158064	MEDI4736	Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors	P2	active not recruiting	30	Memorial Sloan Kettering Cancer Center	May 2017
NCT02962063		Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer	P1/P2	active not recruiting	64	Memorial Sloan Kettering Cancer Center	Nov 2016
NCT03703297	ADRIATIC	Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy	P3	active not recruiting	730	AstraZeneca	Sep 2018
NCT05701488		SIRT With Tremelimumab and Durvalumab for Resectable HCC	P1	recruiting	20	Jiping Wang, MD, PhD	Apr 2023
NCT05883644	SIERRA	Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)	P3	active not recruiting	111	AstraZeneca	Jun 2023
NCT03298451	HIMALAYA	Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma	P3	active not recruiting	1,324	AstraZeneca	Oct 2017
NCT03410615		Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC	P2	active not recruiting	129	Canadian Cancer Trials Group	May 2018
NCT05809869		Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma	P2	recruiting	25	The University of Hong Kong	Feb 2023
NCT03057106		Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC	P2	active not recruiting	301	Canadian Cancer Trials Group	Mar 2017
NCT01843374	Tremelimumab	Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma	P2	active not recruiting	571	MedImmune LLC	May 2013
NCT05383001		Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)	P2	withdrawn	0	AIO-Studien-gGmbH	May 2022
NCT04817826	INFINITY	TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.	P2	active not recruiting	31	Gruppo Oncologico del Nord-Ovest	Apr 2021
NCT03482102	MEDI4736	Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer	P2	active not recruiting	37	Massachusetts General Hospital	May 2018
NCT03784066	DUTRELASCO	Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity	P1/P2	active not recruiting	21	Universitaire Ziekenhuizen KU Leuven	Aug 2018
NCT04073160	TRIO Bladder	TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer	P1	withdrawn	0	Daniel George, MD	Jun 2020
NCT05864755		HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma	P2	unknown	30	Tianjin Medical University Cancer Institute and Hospital	Jun 2023
NCT03704480	IMMUNO-BIL	Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.	P2	active not recruiting	106	GERCOR - Multidisciplinary Oncology Cooperative Group	Nov 2018
NCT03385655		Prostate Cancer Biomarker Enrichment and Treatment Selection	P2	active not recruiting	200	Canadian Cancer Trials Group	Aug 2018
NCT05380713		......SMARTEST Trial......	P2	completed	30	University Health Network, Toronto	May 2022
NCT03581487		Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer	P1/P2	completed	40	M.D. Anderson Cancer Center	Apr 2019
NCT03911557		Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors	P2	completed	14	John L. Villano, MD, PhD	Jun 2019
NCT02499328		Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck	P1/P2	completed	340	AstraZeneca	Aug 2015
NCT06341764		Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma	P2	recruiting	38	National Cancer Institute, Naples	Sep 2023
NCT03549715	NEMIO	NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma	P1/P2	unknown	121	Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie	Dec 2018
NCT02938793		Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors	P2	terminated	92	Prisma Health-Upstate	Dec 2016
NCT03026062		Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	P2	completed	100	M.D. Anderson Cancer Center	May 2017
NCT04107168		Microbiome Immunotherapy Toxicity and Response Evaluation	—	unknown	1,800	CCTU- Cancer Theme	Jul 2020
NCT02788773		Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer	P2	completed	52	Canadian Cancer Trials Group	Dec 2016
NCT04221555		Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma	P2	completed	68	Asan Medical Center	May 2020
NCT05557838	TREMENDOUS	Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma	P3	recruiting	210	AstraZeneca	Feb 2023
NCT02879318		Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma	P2	completed	180	Canadian Cancer Trials Group	Nov 2016
NCT04223648	MEDI4736	Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma	Early P1	withdrawn	0	Yale University	Aug 2020
NCT03212469	ABIMMUNE	A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer	P1/P2	completed	54	Gustave Roussy, Cancer Campus, Grand Paris	Jun 2017
NCT05239169		Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer	P2	completed	40	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	May 2022
NCT02879162		Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours	P2	completed	140	Canadian Cancer Trials Group	Dec 2016
NCT03871036	ICRA	Improve Checkpoint-blockade Response in Advanced Urothelial Cancer	P1/P2	completed	53	The Netherlands Cancer Institute	May 2019
NCT03509012	CLOVER	Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors	P1	completed	105	AstraZeneca	May 2018
NCT03802747		Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases	P1	withdrawn	0	University of Colorado, Denver	Aug 2019
NCT03283605		Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas	P1/P2	active not recruiting	45	Centre hospitalier de l'Université de Montréal (CHUM)	Jul 2018
NCT03249142	INeOV	Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer	P1/P2	completed	69	ARCAGY/ GINECO GROUP	Oct 2017
NCT03046862	MEDI4736	Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer	P2	unknown	31	Seoul National University Hospital	Feb 2017
NCT03518606	MOVIE	Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours	P1/P2	completed	126	UNICANCER	Jun 2018
NCT03075527		A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma	P2	terminated	19	Dana-Farber Cancer Institute	Apr 2017
NCT03982173	MATILDA	Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors	P2	withdrawn	0	Gustave Roussy, Cancer Campus, Grand Paris	Sep 2020
NCT03959293		Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma	P2	active not recruiting	107	Federation Francophone de Cancerologie Digestive	Jul 2019
NCT03753919	DUTHY	Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial	P2	terminated	79	Grupo Espanol de Tumores Neuroendocrinos	Apr 2019
NCT05027425	MEDI4736	Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant	P2	terminated	8	University of Cincinnati	Dec 2021
NCT04287894	Induction	Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment	P1	terminated	18	The Netherlands Cancer Institute	Dec 2018
NCT03019003	ASTX727	Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients	P1	completed	13	Massachusetts General Hospital	Mar 2017
NCT03150836		Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer	P2	withdrawn	0	Terence Friedlander, MD	Oct 2017
NCT03638141	DEB-TACE	CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab	P2	completed	21	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Oct 2019
NCT02953457		Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation	P2	completed	40	Roswell Park Cancer Institute	Jun 2017
NCT02819596	CALYPSO	MEDI4736 Combinations in Metastatic Renal Cell Carcinoma	P2	completed	69	Queen Mary University of London	May 2016
NCT04159974	RICE	RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus	P2	unknown	56	University of Cologne	Sep 2019
NCT03975114	MILES-5	A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)	P2	unknown	460	National Cancer Institute, Naples	Dec 2018
NCT02815995		Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes	P2	completed	57	M.D. Anderson Cancer Center	Aug 2016
NCT03598816	PIVOT-RCC	PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma	P2	withdrawn	0	Washington University School of Medicine	Aug 2020
NCT03237377		Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer	P2	terminated	9	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Dec 2017
NCT03132467		Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer	Early P1	completed	16	M.D. Anderson Cancer Center	Jun 2017
NCT03426657		Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC	P2	completed	120	University of Erlangen-Nürnberg Medical School	Sep 2018
NCT03994393	ILLUMINATE	Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.	P2	unknown	100	University of Sydney	Oct 2018
NCT04156087	MIMIPAC	Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer	P2	completed	12	Baki Topal	May 2020
NCT04625699		Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment	P2	withdrawn	0	Catherine Shu	Dec 2022
NCT02937818		A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer	P2	completed	72	AstraZeneca	Nov 2016
NCT03737968	MEDI4736	Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.	P2	unknown	48	Yonsei University	Jan 2019
NCT00378482		A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.	P2	completed	37	AstraZeneca	Mar 2007
NCT03751761	MEDI4736	GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study	P1/P2	completed	58	Asan Medical Center	Jun 2018
NCT02352948	ARCTIC	A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer	P3	completed	597	AstraZeneca	Jan 2015
NCT03624231	DURTRE-RAD	Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC	P2	completed	18	Ulrich Keilholz	Aug 2018
NCT03452332		Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers	P1	completed	20	M.D. Anderson Cancer Center	Jul 2018
NCT03618134		Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner	P1/P2	terminated	19	Jonsson Comprehensive Cancer Center	Oct 2018
NCT02639026		Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers	P1	completed	53	Abramson Cancer Center at Penn Medicine	Jan 2016
NCT03557918		Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer	P2	completed	26	Matthew Galsky	Nov 2018
NCT03472274	DUTRENEO	Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)	P2	completed	101	Fundacion CRIS de Investigación para Vencer el Cáncer	Oct 2018
NCT02527434		Study of Tremelimumab in Patients With Advanced Solid Tumors	P2	completed	64	AstraZeneca	Nov 2015
NCT02754856		Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery	P1	completed	24	M.D. Anderson Cancer Center	Aug 2016
NCT03202758	MEDITREME	Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC	P1/P2	completed	57	Centre Georges Francois Leclerc	Aug 2017
NCT02821754	HCC	A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)	P2	completed	54	National Cancer Institute (NCI)	Jul 2016
NCT03015129		A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer	P2	completed	80	Memorial Sloan Kettering Cancer Center	Jan 2017
NCT03084471	STRONG	An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.	P3	completed	867	AstraZeneca	Jun 2017
NCT03319316	SOLUTION	Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)	P2	withdrawn	0	European Organisation for Research and Treatment of Cancer - EORTC	Nov 2018
NCT03699449	AMBITION	An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)	P2	unknown	104	Yonsei University	Nov 2018
NCT02592551		MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma	P2	completed	24	Baylor College of Medicine	May 2016
NCT03702179	IMMUNOPRESERVE	Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach	P2	completed	32	Spanish Oncology Genito-Urinary Group	Nov 2018
NCT03317457	MEDISARC	Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma	P2	completed	103	AIO-Studien-gGmbH	Dec 2017
NCT03277482		Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer	P1	terminated	16	Dana-Farber Cancer Institute	Jun 2018
NCT03206073		A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer	P1/P2	completed	34	National Cancer Institute (NCI)	Dec 2017
NCT02626130		Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer	Early P1	completed	29	M.D. Anderson Cancer Center	Mar 2016
NCT02735239		Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer	P1/P2	completed	73	Ludwig Institute for Cancer Research	Jun 2016
NCT02870920		Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer	P2	completed	180	Canadian Cancer Trials Group	Oct 2016
NCT03122496	SBRT	Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer	P1	completed	13	Memorial Sloan Kettering Cancer Center	Apr 2017
NCT03095274	DUNE	Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin	P2	completed	126	Grupo Espanol de Tumores Neuroendocrinos	Apr 2017
NCT05120622	Rideau	Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer	P1/P2	withdrawn	0	University of British Columbia	Sep 2021
NCT05345678		Himalaya Early Access Program	—	approved for marketing	0	AstraZeneca	—
NCT02154490		Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer	—	completed	1,864	SWOG Cancer Research Network	Jul 2014
NCT03450967		Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC	P2	unknown	31	Samsung Medical Center	Apr 2018
NCT03373760		Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer	P2	completed	67	SWOG Cancer Research Network	Nov 2017
NCT03473574	IMMUCHEC	Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients	P2	completed	128	AIO-Studien-gGmbH	May 2018
NCT03292250	TRIUMPH	Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]	P2	completed	180	Seoul National University Hospital	Sep 2017
NCT03101475	ILOC	Synergism of Immunomodulation and Tumor Ablation	P2	completed	22	European Organisation for Research and Treatment of Cancer - EORTC	Nov 2018
NCT02643303		A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers	P1/P2	completed	58	Ludwig Institute for Cancer Research	Dec 2016
NCT03522584		Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	P1/P2	terminated	6	University of Washington	May 2018
NCT03963414		A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC	P1	terminated	1	University of Nebraska	Sep 2020
NCT03608865	MEDI4736	Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing	P2	completed	30	Yonsei University	Sep 2017
NCT03164772		Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC	P1/P2	completed	61	Ludwig Institute for Cancer Research	Dec 2017
NCT03693612		GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors	P1/P2	completed	26	GlaxoSmithKline	Nov 2018
NCT02563925		Brain Irradiation and Tremelimumab in Metastatic Breast Cancer	N/A	completed	28	Memorial Sloan Kettering Cancer Center	Sep 2015
NCT01975831		A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab	P1	completed	104	Ludwig Institute for Cancer Research	Dec 2013
NCT06446570	MEDI4736	Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma	P2	completed	18	Seoul National University Hospital	Sep 2017
NCT03899610	KGOG3046	A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)	P2	unknown	24	Yonsei University	Jul 2019
NCT02551159	KESTREL	Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer	P3	completed	823	AstraZeneca	Oct 2015
NCT03122509		A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer	P2	completed	25	Memorial Sloan Kettering Cancer Center	Apr 2017
NCT03204812		Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer	P2	completed	31	M.D. Anderson Cancer Center	Jul 2017
NCT03144778		Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer	P1	completed	39	M.D. Anderson Cancer Center	Jul 2017
NCT02616185		A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)	P1	terminated	91	Pfizer	Dec 2015
NCT03430895	MEDI4736	Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract	P2	completed	15	Memorial Sloan Kettering Cancer Center	Jan 2018
NCT02536794		MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer	P2	completed	30	Northwestern University	Jan 2016
NCT02311361		Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer	P1/P2	completed	65	National Cancer Institute (NCI)	Mar 2015
NCT02978482	MEDI4736	A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies	P1	completed	26	AstraZeneca	Dec 2016
NCT01938612		A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours	P1	completed	269	AstraZeneca	Sep 2013
NCT02369874	EAGLE	Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer	P3	completed	736	AstraZeneca	Sep 2015
NCT02762006		Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma	P1	completed	29	Moshe Ornstein	Dec 2016
NCT02141542		Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma	P1	completed	15	F. Stephen Hodi, MD	May 2014
NCT02701400		Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer	P2	completed	18	Emory University	Apr 2016
NCT02319044		Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck	P2	completed	267	AstraZeneca	Apr 2015
NCT03275597	SBRT	Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition	P1	terminated	17	University of Wisconsin, Madison	Feb 2018
NCT03089645		MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.	P1	completed	39	MedImmune LLC	Mar 2017
NCT02794883		Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma	P2	completed	36	Northwestern University	Nov 2016
NCT03234153	NITIMIB	Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin	P2	terminated	6	Insel Gruppe AG, University Hospital Bern	Jul 2018
NCT02485990		Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)	P1	terminated	24	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Jan 2016
NCT02261220		A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors	P1	completed	380	MedImmune LLC	Oct 2014
NCT03081923	APACHE	Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors	P2	terminated	36	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Feb 2017
NCT03022500		Pulmonary sarcomatoid_MEDI4736+Treme	P2	completed	32	Seoul National University Hospital	May 2017
NCT03005002		Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver	P1	completed	9	City of Hope Medical Center	Jun 2017
NCT02658214		Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors	P1	completed	32	AstraZeneca	Apr 2016
NCT02586987		A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours	P1	completed	58	AstraZeneca	Dec 2015
NCT02000947	D4190C00006	A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer	P1	completed	459	MedImmune LLC	Oct 2013
NCT03007407		Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy	P2	completed	33	NSABP Foundation Inc	Jul 2017
NCT02705482		A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors	P1	completed	58	MedImmune LLC	Mar 2016
NCT02117219		Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome	P1	completed	67	MedImmune LLC	May 2014
NCT02340975		A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma	P1/P2	completed	114	MedImmune LLC	Mar 2015
NCT02868632		Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer	P1	withdrawn	0	NYU Langone Health	Aug 2016
NCT02549651	D4190C00023	MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)	P1	completed	32	MedImmune LLC	Jul 2016
NCT02718911		A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors	P1	completed	72	Eli Lilly and Company	Jun 2016
NCT03085849		SGI-110 Plus Durvalumab/Tremelimumab in SCLC	P1	completed	2	Catherine Shu	Dec 2017
NCT03430466		Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer	P2	terminated	1	Kyoto Breast Cancer Research Network	Jun 2017
NCT02588131	NIBIT-MESO-1	A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)	P2	unknown	40	Italian Network for Tumor Biotherapy Foundation	Oct 2015
NCT02301130		Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors	P1	completed	64	Kyowa Kirin, Inc.	Nov 2014
NCT02716805		Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant	P1	terminated	6	Ludwig Institute for Cancer Research	Dec 2016
NCT03130764		Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC	P2	withdrawn	0	Columbia University	Mar 2017
NCT02262741		A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer	P1	completed	71	MedImmune LLC	Oct 2014
NCT02558894		Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma	P2	completed	65	AstraZeneca	Nov 2015
NCT01853618		Tremelimumab With Chemoembolization or Ablation for Liver Cancer	P1/P2	completed	61	National Cancer Institute (NCI)	May 2013
NCT02141347		Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma	P1	completed	65	AstraZeneca	May 2014
NCT02179671	MEDI4736	Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer	P2	completed	32	AstraZeneca	Jul 2014
NCT01103635		Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma	P1	completed	25	Abramson Cancer Center at Penn Medicine	Feb 2010
NCT02205333	MEDI6469	A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies	P1/P2	terminated	48	MedImmune LLC	Aug 2014
NCT02040064	GEFTREM	Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients	P1	completed	27	Gustave Roussy, Cancer Campus, Grand Paris	Jan 2014
NCT01655888		The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma	P2	unknown	29	Azienda Ospedaliera Universitaria Senese	Jul 2012
NCT04274816		Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma	P1	completed	13	A.J.M. van den Eertwegh	Jul 2012
NCT01649024		A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma	P2	unknown	29	Azienda Ospedaliera Universitaria Senese	May 2009
NCT00702923	CP-675	CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer	P1	terminated	12	University of Wisconsin, Madison	Jul 2008

Tremelimumab clinical trials: frequently asked questions

How many Tremelimumab clinical trials are there?: 234 Tremelimumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 40 are actively recruiting participants. 97 are marked completed.
Are Tremelimumab clinical trials recruiting in 2026?: Yes — 40 Tremelimumab trials are actively recruiting in 2026, with 206 U.S. sites across 29 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Tremelimumab being studied for?: Tremelimumab is being studied for Hepatocellular Carcinoma, Colorectal Cancer, Bladder Cancer, Breast Cancer, Advanced Solid Tumors and 413 more. The trials are grouped by indication on this page.
What phase is Tremelimumab in?: Tremelimumab clinical trials span 20 Phase 3, 122 Phase 2, 48 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Tremelimumab clinical trials?: The lead sponsor across the most Tremelimumab trials is AstraZeneca, with 111 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Tremelimumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 16, 2026.

Related pages on Hipa.ai:

Tremelimumab overview Tremelimumab evidence & publications